The power struggle at Sinovac has taken another unusual turn with the company's move to implement a "poison pill" defense.
Themis' win comes after the FDA granted the same designation to chikungunya candidates from PaxVax and Valneva.
The company aims to enter the clinic with a pan-flavivirus vaccine against Zika, dengue and yellow fever in 2019.
Here is some other vaccine news of note for the week.
Sanofi has faced more than a year of controversy for its dengue vaccine, and now Philippine officials have revoked Dengvaxia's regulatory approval.
After the buy, Bharat Biotech will be able to make 25 million doses of rabies vaccine each year, its chairman said.
In a phase 1/2 study, Astellas and Affinivax's MAPS-based vaccine will be tested head-to-head against Pfizer's Prevnar 13.
FluGen said its intranasal, "universal" flu vaccine helped protect trial participants against a "highly mismatched" strain.
A former deputy director of the old China FDA has been handed to the prosecutors over suspected duty-related crimes.